Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting

DATE: 04 Jun 2021 CATEGORY: PRESS RELEASE chnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting ISB 1342 IS A…

Continue ReadingIchnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting

Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma

DATE: 06 Aug 2021 CATEGORY: PRESS RELEASE Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma ISB 1442 IS A FIRST-IN-CLASS CD38…

Continue ReadingIchnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma

Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting

DATE: 11 Dec 2021 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting ISB 1442 is a…

Continue ReadingIchnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting

Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody

DATE: 14 Dec 2021 CATEGORY: PRESS RELEASE Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody Almirall is Granted Exclusive Global Rights to Develop…

Continue ReadingIchnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody

Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference

DATE: 18 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference [FOR IMMEDIATE RELEASE]NEW YORK, NYMARCH 18, 2022NEW YORK,…

Continue ReadingIchnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference

Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting

DATE: 23 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting ISB 1442 is…

Continue ReadingIchnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting

Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma

DATE: 09 May 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma First TREAT™ Trispecific Antibody Targeting BCMA and…

Continue ReadingIchnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma

Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442

DATE: 07 July 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001 The US Food and Drug Administration grants orphan drug designation to…

Continue ReadingIchnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442